M. Senbetta

Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review

C. Piech, E. Stepanski, C. Langer, 2012, Supportive Care in Cancer.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.

C. Piech, R. Bailey, F. Vekeman, 2010, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

Ibrutinib therapy for patients with relapsed or refractory mantle cell lymphoma: A budget impact analysis from a U.S. payer perspective.

K. O’Day, R. McKenzie, M. Senbetta, 2014 .

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia

C. Piech, C. Pashos, R. McKenzie, 2011, Supportive Care in Cancer.

Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

S. Sorensen, J. Linnehan, V. Hutchins, 2013, Journal of managed care pharmacy : JMCP.

Economic burden of treatment failure in chronic lymphocytic leukemia patients

P. Lefebvre, M. Lafeuille, M. Senbetta, 2018, Current medical research and opinion.

676 THE ABSENCE OF GOAL SETTING IN THE DIALOGUE BETWEEN METASTATIC PROSTATE CANCER (MCRPC) PATIENTS AND THEIR PHYSICIANS AN OPPORTUNITY FOR SHARED DECISION MAKING

A. Stephenson, R. Bailey, T. Krupski, 2012 .

Balancing efficacy with tolerability: The conversational mechanics of shared decision making in metastatic castration-resistant prostate cancer (mCRPC).

B. Davidson, M. Senbetta, M. Dichiara, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.